Therapeutic Potential of ALK1 Activating Drugs in HHT Models

ALK1 激活药物在 HHT 模型中的治疗潜力

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT (DESCRIPTION) Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant genetic disorder characterized by the development of potentially life-threatening vascular anomalies in several organs in the form of arteriovenous malformations (AVMs). HHT mutations are mostly found in the ALK1 and ENG genes and lead to a loss-of- function in the BMP9/10-ALK1-ENG signaling cascade. Evidence suggests that HHT arise from aberrant reactivation of angiogenesis and endothelial cell (EC)-driven hypervascularization. The overall goal of this program is to implement a screening and characterization strategy aimed at identifying FDA-approved drugs with disease-modifying properties and therapeutic potential in novel cellular and mouse models of HHT. We have screened the NIH clinical collections of FDA-approved drugs to identify molecules capable of activating ALK1 signaling in reporter cells. The immunophilin ligand tacrolimus (FK506) was identified as the most potent ALK1 activator. In preliminary studies, we confirmed that tacrolimus, as well as its analog sirolimus, are potent ALK1 signaling activators in ECs. Of significance, the two analog drugs prevented retinal vascular pathology in the transmammary model of BMP9/10-immunoblocking, an HHT mouse model recently developed in our laboratory. In addition, we determined that tacrolimus efficiently triggered ALK1 activation in primary ECs derived from an HHT patient carrying the well-described disease-causing ALK1-T372fsX mutation. Based on these results, we propose in Aims 1 and 2 of this application to assess and compare the therapeutic potential of tacrolimus and sirolimus in the transmammary model of BMP9/10-immunoblocking and in a new knockin mouse line expressing the HHT ALK1-T372fsX mutation. We will also generate a mini-bank of HHT patient- derived primary ECs, which will be used to delineate the mechanisms by which tacrolimus and sirolimus control ALK1 signaling (Aim 3). We believe that this comprehensive approach in relevant and powerful models of HHT not only will increase our understanding of the molecular underpinnings of the disease, but also will motivate new clinical investigations for HHT.
项目摘要/摘要(描述)

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PHILIPPE MARAMBAUD其他文献

PHILIPPE MARAMBAUD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PHILIPPE MARAMBAUD', 18)}}的其他基金

Angiopoietin-2 Signaling Targeted Therapeutics for Arteriovenous Malformations
血管生成素 2 信号传导靶向治疗动静脉畸形
  • 批准号:
    10420883
  • 财政年份:
    2022
  • 资助金额:
    $ 41.25万
  • 项目类别:
Angiopoietin-2 Signaling Targeted Therapeutics for Arteriovenous Malformations
血管生成素 2 信号传导靶向治疗动静脉畸形
  • 批准号:
    10586049
  • 财政年份:
    2022
  • 资助金额:
    $ 41.25万
  • 项目类别:
mTOR and VEGFR2 pathways in HHT pathogenesis
HHT 发病机制中的 mTOR 和 VEGFR2 通路
  • 批准号:
    10652406
  • 财政年份:
    2020
  • 资助金额:
    $ 41.25万
  • 项目类别:
Promotion of Alzheimers Disease by Alcohol - Role of eCIRP
酒精促进阿尔茨海默病 - eCIRP 的作用
  • 批准号:
    10264903
  • 财政年份:
    2020
  • 资助金额:
    $ 41.25万
  • 项目类别:
mTOR and VEGFR2 pathways in HHT pathogenesis
HHT 发病机制中的 mTOR 和 VEGFR2 通路
  • 批准号:
    10229604
  • 财政年份:
    2020
  • 资助金额:
    $ 41.25万
  • 项目类别:
Promotion of Alzheimers Disease by Alcohol - Role of eCIRP
酒精促进阿尔茨海默病 - eCIRP 的作用
  • 批准号:
    10689797
  • 财政年份:
    2020
  • 资助金额:
    $ 41.25万
  • 项目类别:
mTOR and VEGFR2 pathways in HHT pathogenesis
HHT 发病机制中的 mTOR 和 VEGFR2 通路
  • 批准号:
    10434787
  • 财政年份:
    2020
  • 资助金额:
    $ 41.25万
  • 项目类别:
Promotion of Alzheimers Disease by Alcohol - Role of eCIRP
酒精促进阿尔茨海默病 - eCIRP 的作用
  • 批准号:
    10473796
  • 财政年份:
    2020
  • 资助金额:
    $ 41.25万
  • 项目类别:
Mechanisms of regulation of amyloid-beta metabolism by CALHM1
CALHM1 调节淀粉样蛋白代谢的机制
  • 批准号:
    8346353
  • 财政年份:
    2013
  • 资助金额:
    $ 41.25万
  • 项目类别:
Mechanisms of regulation of amyloid-beta metabolism by CALHM1
CALHM1 调节淀粉样蛋白代谢的机制
  • 批准号:
    8731789
  • 财政年份:
    2013
  • 资助金额:
    $ 41.25万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 41.25万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 41.25万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 41.25万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 41.25万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 41.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 41.25万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 41.25万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 41.25万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 41.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 41.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了